VIP

Mechanism of Action

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide first discovered in the intestine but now known to be widely distributed throughout the body. It functions as both a neurotransmitter and a hormone with profound effects on inflammation, immune function, and tissue homeostasis.

Primary Mechanisms

VPAC Receptor Activation

VIP exerts effects through two main G-protein coupled receptors:

• VPAC1: Widely expressed; mediates most immune and anti-inflammatory effects
• VPAC2: Expressed in CNS and smooth muscle; mediates vasodilation and neuroprotection

Both receptors activate adenylyl cyclase, increasing intracellular cAMP.

Anti-Inflammatory Effects

VIP is one of the most potent endogenous anti-inflammatory peptides:

• Inhibits production of TNF-alpha, IL-6, IL-12
• Reduces NFkB activation
• Decreases macrophage inflammatory response
• Shifts immune response from Th1/Th17 toward Th2/Treg
• Reduces oxidative stress and nitric oxide production

Immunoregulation

• Promotes regulatory T cell (Treg) development
• Inhibits dendritic cell maturation
• Reduces antigen presentation
• Modulates B cell function
• Supports tolerance mechanisms

Neuroprotection

• Protects neurons from toxic insults
• Reduces neuroinflammation
• Supports glial cell function
• May preserve cognitive function

Vasodilation and Bronchodilation

• Relaxes smooth muscle
• Dilates blood vessels
• Opens airways
• Improves tissue perfusion

VIP in CIRS (Chronic Inflammatory Response Syndrome)

In the Shoemaker Protocol for mold illness:

• Addresses dysregulated inflammatory response
• Helps normalize cytokine profiles
• Supports recovery of multiple systems
• Used as final step in comprehensive treatment

Research & Evidence

CIRS/Mold Illness

The primary clinical application:

• Part of Shoemaker CIRS treatment protocol
• Addresses persistent inflammation after biotoxin removal
• Improves multiple biomarkers
• Clinical improvements in fatigue, cognition, and symptoms

Biomarker Changes

• Reduces C4a levels
• Normalizes TGF-beta 1
• Improves MMP-9
• Addresses VEGF dysregulation

Autoimmune Conditions

Research in various autoimmune diseases:

• Rheumatoid arthritis
• Multiple sclerosis
• Inflammatory bowel disease
• Type 1 diabetes

Mechanisms

• Suppresses autoreactive immune responses
• Promotes tolerance
• Reduces disease activity in animal models

Pulmonary Conditions

COVID-19/ARDS

• Aviptadil (VIP) studied in severe COVID
• Showed promise in reducing inflammation
• Improved oxygenation in some studies
• Emergency use authorization sought

Pulmonary Hypertension

• Vasodilatory effects benefit pulmonary circulation
• Reduces right heart strain
• Improves exercise tolerance

Gut Health

Original discovery context:

• Regulates gut motility
• Supports mucosal integrity
• Anti-inflammatory in IBD models
• Protects against gut barrier dysfunction

Neuroprotection

Research demonstrates:

• Protection against ischemic damage
• Preservation of cognitive function
• Support for Parkinson's disease models
• Potential in Alzheimer's research

Dosing

Research Protocols

Shoemaker CIRS Protocol Details

Standard intranasal VIP protocol:

• Starting dose: 50 mcg per nostril, 4x daily
• Total daily dose: 400 mcg
• Duration: minimum 30 days
• Continue until biomarkers normalize

Prerequisites for VIP in CIRS:

• Must complete prior steps of Shoemaker protocol
• Environment must be remediated
• MARCoNS must be treated
• Other inflammatory markers addressed first

Administration Notes

Intranasal (CIRS Protocol)

• Use calibrated nasal spray
• Spray into each nostril
• Remain upright after administration
• Space doses throughout day

Subcutaneous (Research)

• Alternative route for some applications
• May provide more systemic effects
• Requires proper injection technique

Storage

• Refrigerate all preparations
• Protect from light
• Reconstituted solutions: use within 7-14 days
• Lyophilized powder stable long-term when frozen

Pharmacokinetics

Absorption

• Intranasal: Moderate absorption; reaches circulation
• Subcutaneous: Better systemic availability
• Very short plasma half-life limits exposure
• Local effects at nasal mucosa may contribute

Distribution

• Wide tissue distribution
• Present in CNS, gut, lungs, immune tissue
• Binds to VPAC receptors throughout body
• Crosses blood-brain barrier poorly (peripheral administration)

Metabolism

• Rapidly degraded by neutral endopeptidases
• Serum proteases quickly inactivate VIP
• Half-life in plasma only 1-2 minutes
• Frequent dosing necessary

Elimination

• Plasma half-life: 1-2 minutes (extremely short)
• Rapid enzymatic degradation
• No accumulation with normal dosing
• Effects may persist beyond plasma clearance due to receptor dynamics

Synergy & Stacking

VIP + BPC-157

Gut and systemic healing:

• VIP addresses inflammation systemically
• BPC-157 supports local tissue healing
• Complementary for gut recovery
• Both used in functional medicine protocols

VIP + Thymosin Alpha-1

Comprehensive immune support:

• VIP modulates inflammatory response
• TA1 enhances immune surveillance
• Balanced approach to immune dysfunction
• Common in integrative protocols

VIP + KPV

Enhanced anti-inflammatory stack:

• VIP via VPAC receptors
• KPV via melanocortin pathway
• Non-overlapping mechanisms
• Potentially synergistic effects

CIRS Protocol Stack

Complete Shoemaker approach:

• Sequential, not all simultaneous
• Address environment first
• Treat colonizers (MARCoNS)
• Use binders
• VIP as final optimization step

Safety & Side Effects

Known Side Effects

Common

• Nasal congestion or irritation
• Flushing (vasodilation)
• Mild hypotension
• Headache

Uncommon

• Diarrhea (gut motility effects)
• Palpitations
• Dizziness
• Nausea

Cardiovascular Considerations

VIP is a potent vasodilator:

• Monitor blood pressure initially
• Start with lower doses
• Use caution with existing hypotension
• May interact with BP medications

Lipase Concern

Historical concern addressed:

• Early protocols noted lipase elevation
• Modern protocols (intranasal) show less effect
• Monitor lipase if using high doses
• Generally not clinically significant with standard dosing

Contraindication Details

Severe Hypotension

• VIP can worsen low blood pressure
• Ensure adequate hydration
• Consider salt/electrolyte status

Pregnancy

• Insufficient safety data
• Effects on smooth muscle uncertain
• Avoid during pregnancy

Monitoring

CIRS Protocol Monitoring

Biomarkers to track:

• C4a (complement activation)
• TGF-beta 1 (fibrosis marker)
• MMP-9 (matrix metalloproteinase)
• VEGF (vascular endothelial growth factor)
• MSH (melanocyte stimulating hormone)

General Monitoring

• Blood pressure (especially initially)
• Symptoms response
• Quality of life measures
• Inflammatory markers if available

Labs to Consider

Before and during treatment:

• Complete metabolic panel
• Lipase (if concern)
• Inflammatory markers (CRP, ESR)
• Condition-specific labs

Regulatory Status

Current Status

Investigational Status

• Aviptadil studied for ARDS/COVID
• Multiple autoimmune trials ongoing
• Growing evidence base
• Not yet standard of care for any condition

Legal Considerations

• Available from compounding pharmacies with prescription
• Research chemical availability varies
• Quality control essential
• Work with experienced practitioners

References